๋ธ๋ก๋ชจํฌ๋ฆฝํด
๋ธ๋ก๋ชจํฌ๋ฆฝํด์ ๋ฐํฉ์ฑ ๋งฅ๊ฐ ์์นผ๋ก์ด๋ ์ ๋์ฒด๋ก **๋ํ๋ฏผ ์์ฉ์ ** ๋ฐ **ํ๋ก๋ฝํด ์ต์ ์ **๋ก ์์ฉํฉ๋๋ค. - **๊ฐ**: ์์ ์ค์ ๋๋ ์์์์ ์ ์ฌ์ฉ๋ฉ๋๋ค(์์ฅ๊ด ๋ถ์์ฉ์ด ์ ์ ์นด๋ฒ ๋ฅด๊ณจ๋ฆฐ์ด ๋ ์ ํธ๋จ). - **๊ณ ์์ด**: ์ธ์๋ฆฐ ์๊ตฌ๋์ ์ค์ด๊ธฐ ์ํด ๋ง๋จ๋น๋์ฆ์ ๋ณด์กฐ ์น๋ฃ์ ๋ก ๊ฐํน ์ฌ์ฉ๋ฉ๋๋ค. - **๋ง**: ์ญ์ฌ์ ์ผ๋ก ๋ํ์์ฒด ์ค์ฝ ๊ธฐ๋ฅ ์ฅ์ (PPID/๋ง ์ฟ ์ฑ ์ฆํ๊ตฐ) ๋๋ ๋ํ์์ฒด ์ ์ข ์ ์ฌ์ฉ๋์์ผ๋, ํ์ฌ๋ ํ๋ฅด๊ณจ๋ฆฌ๋๊ฐ ํ์ค ์น๋ฃ์ ์ ๋๋ค. > **์์ ์์ **: ๋ธ๋ก๋ชจํฌ๋ฆฝํด์ ๊ฐ์์ ์ฌ๊ฐํ ๊ตฌํ ๋ฅผ ์ ๋ฐํ๋ ๊ฒ์ผ๋ก ์ ๋ช ์ด ๋์ผ๋ฉฐ, ์ด๋ก ์ธํด ์์์ ์ ์ฉ์ฑ์ด ์ ํ๋ฉ๋๋ค. ์์๊ณผ ํจ๊ป ํฌ์ฌํ๊ฑฐ๋ ํญ๊ตฌํ ์ ์ฌ์ฉ์ด ํ์ํ ์ ์์ต๋๋ค.
์์ฉ ๊ธฐ์ : Bromocriptine acts primarily by stimulating **postsynaptic dopamine (D2) receptors** in the hypothalamus and anterior pituitary gland. - **Prolactin Inhibition**: Dopamine receptor stimulation โ release of prolactin-inhibitory factor (PIF) โ direct inhibition of prolactin secretion from the anterior pituitary. - **Acromegaly**: In certain pituitary adenomas, paradoxical suppression of growth hormone (GH) secretion occurs via dopaminergic stimulation. - **CNS Effects**: Activates dopaminergic receptors in the neostriatum of the brain, which can influence motor control and behavior.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Adjunctive treatment of acromegaly ยท Initial dose of 0.2 mg (total dose) ยท Unspecified ยท Unspecified ยท May reduce insulin requirements.
- Treatment of pituitary adenoma ยท 0.03-0.09 mg/kg (30-90 micrograms/kg) twice daily PO or SC ยท PO/SC ยท twice daily ยท Its use is limited. Note: ARCI UCGFS Class 2 Drug.
- Treatment of pituitary adenoma ยท 5 mg (total dose) IM q12h ยท IM ยท q12h ยท To prepare an injectable formulation for IM use from oral dosage forms: Bromocriptine mesylate 70 mg is added to 7 mL of a solution of 80% normal saline and 20% absolute alcohol (v/v). Final concentration is 1% (10 mg/mL).
- Treatment of pseudocyesis (pseudopregnancy) ยท 10-100 micrograms/kg PO daily in divided doses until lactation ceases ยท PO ยท daily in divided doses ยท until lactation ceases ยท Vomiting, depression and anorexia are common side effects, usually more problematic than the lactation.
- Treatment of pseudocyesis (pseudopregnancy) ยท 10-100 micrograms/kg PO twice daily for 10-14 days ยท PO ยท twice daily ยท 10-14 days ยท Vomiting is very common; reducing dose and administering after meals may help.
- Treatment of pseudocyesis (pseudopregnancy) ยท 10-50 micrograms/kg PO at least twice a day ยท PO ยท at least twice a day
- Pregnancy termination after mismating ยท 50-100 micrograms/kg PO or IM twice daily for 4-7 days ยท PO/IM ยท twice daily ยท 4-7 days ยท From day 35-45 after LH surge. Not uniformly effective and may cause vomiting at this dosage (a peripheral acting antiemetic 30 minutes before dose may be helpful).
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Hypertension
- Pregnancy (in humans, documented teratogenicity not established but contraindicated)
- Nursing/lactating animals (interferes with lactation)
์ด์๋ฐ์
- Nausea
- Vomiting (highly prevalent in dogs)
- Sedation
- Fatigue
- Hypotension
- Anorexia
- Depression
- Trembling
- Diarrhea
- Tachycardia
์ฝ๋ฌผ ์ํธ์์ฉ
- Alcohol ยท May cause a disulfiram-type reaction
- Butyrophenones (e.g., haloperidol, azaperone) ยท May increase prolactin concentrations; bromocriptine doses may need to be increased
- Amitriptyline ยท May increase prolactin concentrations; bromocriptine doses may need to be increased
- Phenothiazines ยท May increase prolactin concentrations; bromocriptine doses may need to be increased
- Reserpine ยท May increase prolactin concentrations; bromocriptine doses may need to be increased
- Cyclosporine ยท May elevate cyclosporine levels
- Erythromycin ยท May increase bromocriptine levels
- Clarithromycin ยท May increase bromocriptine levels
- Estrogens or Progestins ยท May interfere with the effects of bromocriptine
- Ergot Alkaloids ยท Not recommended; concurrent use has caused severe hypertension and myocardial infarction in humans
- Hypotensive Medications ยท May cause additive hypotension
- MAO Inhibitors (including amitraz, selegiline) ยท Avoid use of bromocriptine with these compounds
- Metoclopramide ยท May cause prolactin release in dogs, negating the effects of bromocriptine for treating pseudopregnancy
๋ชจ๋ํฐ๋ง
- Clinical efficacy (dependent upon the reason for use)
- Blood pressure (especially if patients exhibit clinical signs associated with hypotension)
๊ณผ์ฉ๋
Overdosage may cause **vomiting, severe nausea, and profound hypotension**. - **Clinical Signs in Dogs**: Common findings recorded in decreasing frequency include vomiting, trembling, diarrhea, subdued behavior, and tachycardia. - **Treatment**: Standardized gut removal techniques should be employed when applicable, though emesis often occurs spontaneously. Institute cardiovascular monitoring (blood pressure, heart rate) and provide supportive care as needed.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.